Drug Profile


Alternative Names: CP-675; CP-675,206; Ticilimumab

Latest Information Update: 17 Feb 2017

Price : $50

At a glance

  • Originator Pfizer
  • Developer Amgen; AstraZeneca; Azienda Ospedaliera Universitaria Senese; Canadian Cancer Trials Group; Immunocore; Kyoto Breast Cancer Research Network; M. D. Anderson Cancer Center; MedImmune; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Northwestern University; Pfizer
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Interleukin 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Head and neck cancer; Mesothelioma; Non-small cell lung cancer
  • Phase II Breast cancer; Endometrial cancer; Gastric cancer; Glioblastoma; Hepatocellular carcinoma; Pancreatic cancer; Prostate cancer; Sarcoma; Small cell lung cancer; Solid tumours
  • Phase I/II Malignant melanoma; Peritoneal cancer
  • Phase I Colorectal cancer; Diffuse large B cell lymphoma; Renal cell carcinoma
  • No development reported Gastrointestinal cancer; Urogenital cancer

Most Recent Events

  • 17 Feb 2017 Seoul National University Hospital plans a phase II trial for Biliary cancer in South Korea (NCT03046862)
  • 15 Feb 2017 AstraZeneca plans a phase III trial for Small cell lung cancer (Late-stage disease, Combination therapy, Metastatic disease) in USA, Argentina, Austria, Bulgaria, Czech republic, Germany, Hungary, Israel, Italy, South Korea, Netherlands, Russia, Slovakia, Spain, Taiwan, Turkey and Ukraine (NCT03043872)
  • 17 Jan 2017 M.D. Anderson Cancer Center and AstraZeneca plan a phase II trial for Fallopian tube cancer, Peritoneal cancer and Ovarian cancer (Recurrent, Combination therapy, Second-line therapy) in USA (NCT03026062)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top